Uptake Medical Technology, Inc.
7
1
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
28.6%
2 terminated/withdrawn out of 7 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
A Randomized Controlled Trial of InterVapor® in France - The TARGET Trial
Role: lead
Vapor Ablation for Localized Cancer Lesions
Role: lead
Post-Market BTVA Registry
Role: lead
Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE)
Role: lead
A Pilot Study to Assess Treatment of Patients With Homogeneous Emphysema Using Sequential Segmental Bronchoscopic Thermal Vapor Ablation (NEXT STEP)
Role: lead
Post-Market Optimization Study of the EMPOWER® RF Catheter to Ablate Soft Tissue Lesions in the Lung
Role: collaborator
Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors
Role: collaborator
All 7 trials loaded